Chiesi Advances Its Carbon Minimal Inhaler Journey as European Submissions for Its Single Inhaler Triple Therapy (SITT) and ICS/LABA Combination Next-Generation Propellant pMDIs Are Validated

Contributed by: Business Wire

Tags

Biotechnology

Pharmaceutical

Sustainability

Environment

General Health

Health

Green Technology

Other Health

Carbon Minimal Inhaler

More Like This

Chiesi Group ("Chiesi"), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, today announced an expansion of their long-standing partnership, increasing pressurized metered dose inhaler (pMDI) manufacturing capacity at Bespak’s Holmes Chapel site to support the next phase of Chiesi’s Carbon Minimal Inhaler (CMI) program.

Chiesi and Bespak Partner to Advance Carbon Minimal Inhaler Production With UK Manufacturing Site

MHRA approves world's first lower-carbon beclometasone inhalers for patients with asthma

Trixeo Aerosphere approved in the UK as first inhaled respiratory medicine using next-generation propellant with near-zero Global Warming Potential

Mundipharma and Vectura announce plans to reformulate flutiform® (fluticasone propionate/formoterol fumarate) pressurised metered-dose inhaler (pMDI) as a commitment to reducing the product’s carbon footprint

Kindeva Drug Delivery Invests in Second Manufacturing Line for Greener Inhalers at UK Manufacturing Site

Orbia Fluor & Energy Materials Advances Project to Increase Production of Zephex® 152a in UK

Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications

Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights